JP2018528783A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528783A5 JP2018528783A5 JP2018515456A JP2018515456A JP2018528783A5 JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5 JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018515456 A JP2018515456 A JP 2018515456A JP 2018528783 A5 JP2018528783 A5 JP 2018528783A5
- Authority
- JP
- Japan
- Prior art keywords
- duplex
- modified
- modified oligonucleotide
- extrahepatic
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 212
- 239000002777 nucleoside Substances 0.000 claims description 172
- 102000039446 nucleic acids Human genes 0.000 claims description 148
- 108020004707 nucleic acids Proteins 0.000 claims description 148
- 150000007523 nucleic acids Chemical class 0.000 claims description 148
- 125000003835 nucleoside group Chemical group 0.000 claims description 100
- 150000001875 compounds Chemical class 0.000 claims description 77
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 60
- 210000004185 liver Anatomy 0.000 claims description 17
- 125000002619 bicyclic group Chemical group 0.000 claims description 16
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 13
- 150000004713 phosphodiesters Chemical class 0.000 claims description 12
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 claims description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 8
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims description 5
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 210000002460 smooth muscle Anatomy 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 4
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 56
- 210000004027 cell Anatomy 0.000 description 48
- 230000000692 anti-sense effect Effects 0.000 description 37
- -1 TNF- [alpha] Proteins 0.000 description 35
- 230000000694 effects Effects 0.000 description 32
- 125000005647 linker group Chemical group 0.000 description 32
- 239000008194 pharmaceutical composition Substances 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 102100032187 Androgen receptor Human genes 0.000 description 16
- 108010080146 androgen receptors Proteins 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 12
- 102100038369 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Human genes 0.000 description 8
- 101001082110 Acanthamoeba polyphaga mimivirus Eukaryotic translation initiation factor 4E homolog Proteins 0.000 description 8
- 108091010877 Allograft inflammatory factor 1 Proteins 0.000 description 8
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 8
- 102100030461 Alpha-ketoglutarate-dependent dioxygenase FTO Human genes 0.000 description 8
- 102100034594 Angiopoietin-1 Human genes 0.000 description 8
- 102100025668 Angiopoietin-related protein 3 Human genes 0.000 description 8
- 102100022802 BTB/POZ domain-containing protein KCTD15 Human genes 0.000 description 8
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 8
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 8
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 8
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 8
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 8
- 101710101477 Carbohydrate-responsive element-binding protein Proteins 0.000 description 8
- 102100037403 Carbohydrate-responsive element-binding protein Human genes 0.000 description 8
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 8
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 8
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 8
- 101001082109 Danio rerio Eukaryotic translation initiation factor 4E-1B Proteins 0.000 description 8
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 description 8
- 102100039577 ETS translocation variant 5 Human genes 0.000 description 8
- 108010074864 Factor XI Proteins 0.000 description 8
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 8
- 102100040890 Glucagon receptor Human genes 0.000 description 8
- 102100036702 Glucosamine-6-phosphate isomerase 2 Human genes 0.000 description 8
- 102100020948 Growth hormone receptor Human genes 0.000 description 8
- 102100035364 Growth/differentiation factor 3 Human genes 0.000 description 8
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 8
- 101000605571 Homo sapiens 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Proteins 0.000 description 8
- 101001062620 Homo sapiens Alpha-ketoglutarate-dependent dioxygenase FTO Proteins 0.000 description 8
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 8
- 101000693085 Homo sapiens Angiopoietin-related protein 3 Proteins 0.000 description 8
- 101000974798 Homo sapiens BTB/POZ domain-containing protein KCTD15 Proteins 0.000 description 8
- 101001049859 Homo sapiens Calcium-activated potassium channel subunit alpha-1 Proteins 0.000 description 8
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 8
- 101000930020 Homo sapiens Diacylglycerol O-acyltransferase 2 Proteins 0.000 description 8
- 101000813745 Homo sapiens ETS translocation variant 5 Proteins 0.000 description 8
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 8
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 description 8
- 101001072480 Homo sapiens Glucosamine-6-phosphate isomerase 2 Proteins 0.000 description 8
- 101001075287 Homo sapiens Growth hormone receptor Proteins 0.000 description 8
- 101001023986 Homo sapiens Growth/differentiation factor 3 Proteins 0.000 description 8
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 description 8
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 8
- 101000604641 Homo sapiens Katanin p60 ATPase-containing subunit A1 Proteins 0.000 description 8
- 101000978418 Homo sapiens Melanocortin receptor 4 Proteins 0.000 description 8
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 8
- 101001013994 Homo sapiens Mitochondrial carrier homolog 2 Proteins 0.000 description 8
- 101001013832 Homo sapiens Mitochondrial peptide methionine sulfoxide reductase Proteins 0.000 description 8
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 8
- 101000969961 Homo sapiens Neurexin-3 Proteins 0.000 description 8
- 101000969963 Homo sapiens Neurexin-3-beta Proteins 0.000 description 8
- 101000973623 Homo sapiens Neuronal growth regulator 1 Proteins 0.000 description 8
- 101000603202 Homo sapiens Nicotinamide N-methyltransferase Proteins 0.000 description 8
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 8
- 101001003584 Homo sapiens Prelamin-A/C Proteins 0.000 description 8
- 101000981737 Homo sapiens Protein lifeguard 2 Proteins 0.000 description 8
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 8
- 101000707152 Homo sapiens SH2B adapter protein 1 Proteins 0.000 description 8
- 101000898985 Homo sapiens Seipin Proteins 0.000 description 8
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 description 8
- 101000891620 Homo sapiens TBC1 domain family member 1 Proteins 0.000 description 8
- 101000962461 Homo sapiens Transcription factor Maf Proteins 0.000 description 8
- 101000597758 Homo sapiens Transmembrane protein 18 Proteins 0.000 description 8
- 101001087394 Homo sapiens Tyrosine-protein phosphatase non-receptor type 1 Proteins 0.000 description 8
- 102100038197 Katanin p60 ATPase-containing subunit A1 Human genes 0.000 description 8
- 102000016267 Leptin Human genes 0.000 description 8
- 108010092277 Leptin Proteins 0.000 description 8
- 102100023724 Melanocortin receptor 4 Human genes 0.000 description 8
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 8
- 102100031332 Mitochondrial carrier homolog 2 Human genes 0.000 description 8
- 102100031767 Mitochondrial peptide methionine sulfoxide reductase Human genes 0.000 description 8
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 8
- 102100021310 Neurexin-3 Human genes 0.000 description 8
- 102100022223 Neuronal growth regulator 1 Human genes 0.000 description 8
- 102100038951 Nicotinamide N-methyltransferase Human genes 0.000 description 8
- 108010062309 Nuclear Receptor Interacting Protein 1 Proteins 0.000 description 8
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 8
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 8
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 8
- 102100029558 Nuclear receptor-interacting protein 1 Human genes 0.000 description 8
- 108010016731 PPAR gamma Proteins 0.000 description 8
- 102000017795 Perilipin-1 Human genes 0.000 description 8
- 108010067162 Perilipin-1 Proteins 0.000 description 8
- 102000017794 Perilipin-2 Human genes 0.000 description 8
- 108010067163 Perilipin-2 Proteins 0.000 description 8
- 102000001486 Perilipin-3 Human genes 0.000 description 8
- 108010068633 Perilipin-3 Proteins 0.000 description 8
- 102000001487 Perilipin-4 Human genes 0.000 description 8
- 108010068636 Perilipin-4 Proteins 0.000 description 8
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 8
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 8
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 8
- 102100026531 Prelamin-A/C Human genes 0.000 description 8
- 102100024135 Protein lifeguard 2 Human genes 0.000 description 8
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 8
- 101000613608 Rattus norvegicus Monocyte to macrophage differentiation factor Proteins 0.000 description 8
- 102000007156 Resistin Human genes 0.000 description 8
- 108010047909 Resistin Proteins 0.000 description 8
- 102100031770 SH2B adapter protein 1 Human genes 0.000 description 8
- 108091006587 SLC13A5 Proteins 0.000 description 8
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 8
- 102100021463 Seipin Human genes 0.000 description 8
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 8
- 102100035210 Solute carrier family 13 member 5 Human genes 0.000 description 8
- 102100040238 TBC1 domain family member 1 Human genes 0.000 description 8
- 101150050957 TNKS gene Proteins 0.000 description 8
- 102000003567 TRPV4 Human genes 0.000 description 8
- 101150098315 TRPV4 gene Proteins 0.000 description 8
- 102000004893 Transcription factor AP-2 Human genes 0.000 description 8
- 108090001039 Transcription factor AP-2 Proteins 0.000 description 8
- 102100039189 Transcription factor Maf Human genes 0.000 description 8
- 102100035318 Transmembrane protein 18 Human genes 0.000 description 8
- 102100033001 Tyrosine-protein phosphatase non-receptor type 1 Human genes 0.000 description 8
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 8
- 229940039781 leptin Drugs 0.000 description 8
- 102000005861 leptin receptors Human genes 0.000 description 8
- 108010019813 leptin receptors Proteins 0.000 description 8
- NJHLGKJQFKUSEA-UHFFFAOYSA-N n-[2-(4-hydroxyphenyl)ethyl]-n-methylnitrous amide Chemical compound O=NN(C)CCC1=CC=C(O)C=C1 NJHLGKJQFKUSEA-UHFFFAOYSA-N 0.000 description 8
- 235000021092 sugar substitutes Nutrition 0.000 description 8
- 239000003765 sweetening agent Substances 0.000 description 8
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000005153 frontal cortex Anatomy 0.000 description 6
- 210000003497 sciatic nerve Anatomy 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 210000003594 spinal ganglia Anatomy 0.000 description 6
- 210000000427 trigeminal ganglion Anatomy 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 208000005400 Synovial Cyst Diseases 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102100034608 Angiopoietin-2 Human genes 0.000 description 4
- 102000049320 CD36 Human genes 0.000 description 4
- 108010045374 CD36 Antigens Proteins 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- 102100021158 Double homeobox protein 4 Human genes 0.000 description 4
- 108010044191 Dynamin II Proteins 0.000 description 4
- 102100021238 Dynamin-2 Human genes 0.000 description 4
- 102100024108 Dystrophin Human genes 0.000 description 4
- 102100022447 Eukaryotic translation initiation factor 4E-binding protein 2 Human genes 0.000 description 4
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 4
- 101000968549 Homo sapiens Double homeobox protein 4 Proteins 0.000 description 4
- 101001053946 Homo sapiens Dystrophin Proteins 0.000 description 4
- 101000678283 Homo sapiens Eukaryotic translation initiation factor 4E-binding protein 2 Proteins 0.000 description 4
- 101001129187 Homo sapiens Patatin-like phospholipase domain-containing protein 2 Proteins 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 description 4
- 102100022437 Myotonin-protein kinase Human genes 0.000 description 4
- 102100031248 Patatin-like phospholipase domain-containing protein 2 Human genes 0.000 description 4
- 108091006269 SLC5A2 Proteins 0.000 description 4
- 101001053942 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Diphosphomevalonate decarboxylase Proteins 0.000 description 4
- 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 description 4
- 208000026062 Tissue disease Diseases 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 210000001593 brown adipocyte Anatomy 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 201000006938 muscular dystrophy Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 210000003635 pituitary gland Anatomy 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 210000000636 white adipocyte Anatomy 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 125000004417 unsaturated alkyl group Chemical group 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 101710203526 Integrase Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108091030071 RNAI Proteins 0.000 description 2
- 230000001668 ameliorated effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009368 gene silencing by RNA Effects 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 125000001245 hexylamino group Chemical group [H]N([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical group OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010068871 Myotonic dystrophy Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562233292P | 2015-09-25 | 2015-09-25 | |
| US62/233,292 | 2015-09-25 | ||
| PCT/US2016/053836 WO2017053999A1 (en) | 2015-09-25 | 2016-09-26 | Conjugated antisense compounds and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018528783A JP2018528783A (ja) | 2018-10-04 |
| JP2018528783A5 true JP2018528783A5 (enExample) | 2019-11-07 |
Family
ID=58387451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515456A Pending JP2018528783A (ja) | 2015-09-25 | 2016-09-26 | コンジュゲートアンチセンス化合物及びその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US11116843B2 (enExample) |
| EP (1) | EP3353306A4 (enExample) |
| JP (1) | JP2018528783A (enExample) |
| WO (1) | WO2017053999A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7043078B2 (ja) | 2016-09-23 | 2022-03-29 | 国立大学法人 東京医科歯科大学 | 血液脳関門通過型ヘテロ２本鎖核酸 |
| EP3662060A2 (en) | 2017-08-03 | 2020-06-10 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
| CA3099522C (en) * | 2017-09-19 | 2024-10-08 | Univ Alberta | GAPMERES AND METHODS OF USING THESE FOR THE TREATMENT OF MUSCULAR DYSTROPHY |
| JP2021506239A (ja) * | 2017-12-14 | 2021-02-22 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 複合アンチセンス化合物及びその使用 |
| CA3088112A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
| KR102839166B1 (ko) | 2018-01-12 | 2025-07-28 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도 |
| IL320427A (en) | 2018-02-21 | 2025-06-01 | Bristol Myers Squibb Co | CAMK2D antisense oligonucleotides and their uses |
| EP3766972B1 (en) | 2018-03-14 | 2025-04-23 | Institute of Science Tokyo | Nucleic acid complex |
| WO2019182294A1 (ko) * | 2018-03-19 | 2019-09-26 | 주식회사 케이티 | 비디오 신호 처리 방법 및 장치 |
| WO2019181946A1 (ja) | 2018-03-19 | 2019-09-26 | 国立大学法人東京医科歯科大学 | 毒性が軽減した核酸 |
| WO2019182109A1 (ja) * | 2018-03-22 | 2019-09-26 | 国立大学法人東京医科歯科大学 | ヘテロ核酸のｂｂｂ通過脂質リガンド |
| US20220064636A1 (en) * | 2018-10-05 | 2022-03-03 | Ionis Pharmaceuticals, Inc. | Modified oligomeric compounds and uses thereof |
| CN120290561A (zh) * | 2019-03-29 | 2025-07-11 | 田边三菱制药株式会社 | 用于调节dux4的表达的化合物、方法和医药组合物 |
| CN113677374A (zh) * | 2019-04-08 | 2021-11-19 | 国立大学法人东京医科齿科大学 | 肌疾病治疗用药物组合物 |
| JP7737667B2 (ja) * | 2019-09-18 | 2025-09-11 | 国立大学法人東京科学大学 | 核酸複合体 |
| WO2021070959A1 (ja) * | 2019-10-11 | 2021-04-15 | 国立大学法人東京医科歯科大学 | 修飾ヘテロ核酸 |
| EP4055166A2 (en) * | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| BR112022013686A2 (pt) * | 2020-01-10 | 2022-09-06 | Dyne Therapeutics Inc | Complexos de direcionamento a músculo e usos dos mesmos para tratar distrofia miotônica |
| CN115516092B (zh) * | 2020-09-30 | 2025-05-16 | 亿腾医药（苏州）有限公司 | 血管生成素样3(ANGPTL3)的siRNA及其用途 |
| WO2022106695A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
| WO2023178144A2 (en) | 2022-03-16 | 2023-09-21 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
| AU2023245603A1 (en) | 2022-03-28 | 2024-11-07 | Empirico Inc. | Modified oligonucleotides |
| US20250304957A1 (en) | 2022-05-13 | 2025-10-02 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| WO2024238385A2 (en) | 2023-05-12 | 2024-11-21 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
| WO2024257861A1 (ja) * | 2023-06-16 | 2024-12-19 | 日産化学株式会社 | 脂質結合オリゴヌクレオチド又はその複合体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| EP1937066A4 (en) | 2005-08-18 | 2008-12-24 | Alnylam Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF NERVOUS DISEASES |
| AU2008340354B2 (en) * | 2007-12-04 | 2014-04-17 | Alnylam Pharmaceuticals, Inc. | Folate-iRNA conjugates |
| US20100048676A1 (en) | 2008-08-04 | 2010-02-25 | University Of Rochester | Non-androgen dependent roles for androgen receptor in liver cancer |
| US20100222417A1 (en) | 2008-11-26 | 2010-09-02 | Alnylam Pharmaceuticals | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues |
| PT2396038E (pt) * | 2009-02-12 | 2016-02-19 | Curna Inc | Tratamento das doenças associadas com o factor neurotrófico derivado do cérebro (bdnf) por inibição do produto antisenso natural da transcrição para bdnf |
| KR20180105730A (ko) | 2010-07-19 | 2018-09-28 | 아이오니스 파마수티컬즈, 인코포레이티드 | 근육긴장성 이영양증-단백질 키나제(dmpk) 발현의 조절 방법 |
| EP3533873A1 (en) * | 2011-09-14 | 2019-09-04 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
| EP2791335B1 (en) | 2011-12-16 | 2018-11-14 | National University Corporation Tokyo Medical and Dental University | Chimeric double-stranded nucleic acid |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| CA2901983A1 (en) | 2013-03-01 | 2014-09-04 | National University Corporation Tokyo Medical And Dental University | Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent |
| KR102482890B1 (ko) | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| EP3004347B1 (en) | 2013-05-30 | 2018-09-26 | National University Corporation Tokyo Medical and Dental University | Double-stranded agents for delivering therapeutic oligonucleotides |
| WO2014203518A1 (en) | 2013-06-16 | 2014-12-24 | National University Corporation Tokyo Medical And Dental University | Double-stranded antisense nucleic acid with exon-skipping effect |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| US12139542B2 (en) * | 2014-05-27 | 2024-11-12 | Trustees Of Boston University | Inhibitors of aortic carboxypeptidase-like protein (ACLP) |
| EP3180426B1 (en) * | 2014-08-17 | 2019-12-25 | The Broad Institute, Inc. | Genome editing using cas9 nickases |
| US20210052631A1 (en) | 2015-09-25 | 2021-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
-
2016
- 2016-09-26 US US15/761,786 patent/US11116843B2/en active Active
- 2016-09-26 WO PCT/US2016/053836 patent/WO2017053999A1/en not_active Ceased
- 2016-09-26 JP JP2018515456A patent/JP2018528783A/ja active Pending
- 2016-09-26 EP EP16849895.4A patent/EP3353306A4/en not_active Withdrawn
-
2021
- 2021-08-10 US US17/398,490 patent/US20220023429A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528783A5 (enExample) | ||
| US11116843B2 (en) | Conjugated antisense compounds and their use | |
| RU2501803C2 (ru) | Композиции и способы модуляции экспрессии рецептора фактора роста фибробластов 4 (fgfr4) | |
| JP5763539B2 (ja) | ５’及び２’ビス置換ヌクレオシド及びそれから製造されるオリゴマー化合物 | |
| US9428750B2 (en) | Oligomeric compounds comprising tricyclic nucleosides and methods for their use | |
| RU2015151199A (ru) | Сопряженные антисмысловые соединения и их применение | |
| CN110846316B (zh) | 在基因沉默中具有降低的脱靶效应的una寡聚物 | |
| CN114025848A (zh) | 用于调节剪接和翻译的方法和组合物 | |
| JP2021072862A (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| US20160186175A1 (en) | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom | |
| US9249178B2 (en) | Tricyclic nucleosides and oligomeric compounds prepared therefrom | |
| KR20200104347A (ko) | 포스포로디티오에이트 인터뉴클레오시드 연결을 포함하는 갭머 올리고뉴클레오티드 | |
| EP3516062A1 (en) | Myostatin irna compositions and methods of use thereof | |
| US20160186174A1 (en) | Substituted morpholino compounds analogs thereof and oligomeric compounds prepared therefrom | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| US20220098595A1 (en) | Nr2e3 expression reducing oligonucleotides, compositions containing the same, and methods of their use | |
| JPWO2021030213A5 (enExample) | ||
| US20230089502A1 (en) | Products and compositions | |
| JP6934695B2 (ja) | 核酸医薬とその使用 | |
| JP2023531249A (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| CN117813383B (zh) | 用于抑制CIDEB基因表达的siRNA、药物及其应用 | |
| EP3914713A1 (en) | Nrl expression reducing oligonucleotides, compositions containing the same, and methods of their use | |
| US20250368998A1 (en) | Nucleotide analogues, and preparation and application thereof | |
| WO2020044349A1 (en) | Compounds, cojugates and compositions for use in the methods for trans-membrane delivery of molecules | |
| DE102022124232A1 (de) | Antisense-Oligonukleotide für die Behandlung des Joubert-Syndroms |